SCHEMBL2175386

SCHEMBL2175386

COC(=O)c1ccc2c(c1)c(S(N)(=O)=O)cn2C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 13/20 0.52
CA12 O43570 6/20 0.52
CA1 P00915 5/20 0.45
CA2 P00918 5/20 0.45
CA4 P22748 1/20 0.45
CA14 Q9ULX7 2/20 0.44
CPT2 P23786 1/20 0.44
CPT1A P50416 1/20 0.44
CPT1B Q92523 1/20 0.44
NR4A2 P43354 2/20 0.43
CA7 P43166 1/20 0.43
XDH P47989 1/20 0.43
CA5A P35218 1/20 0.42
STS P08842 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178801 0.89 CA9 (0.45) CA9CA12CA1CA2CA4
SCHEMBL2175814 0.86 CPT2 (0.46) CA9CA12CA1CA2CA14
SCHEMBL3156690 0.82 CA9 (0.47) CA9CA12CA1CA2CA4
SCHEMBL22538729 0.81 NR4A2 (0.49) CA9CA12CA1CA2CA14
SCHEMBL15687469 0.80 NR4A2 (0.51) CA9CA12CA1CA2CA14
SCHEMBL13806396 0.80 KDM4E (0.51) CA9CA12CA1CA2CA14
SCHEMBL1933762 0.77 MAPT (0.51) CA9CA12CA1CA2CA14
SCHEMBL14427691 0.76 NR4A2 (0.47) CA9CA12CA1CA2CA14
SCHEMBL2175671 0.76 ALDH1A1 (0.43) CA9CA12CA1CA2CA14
SCHEMBL13248558 0.75 MTNR1A (0.52) NR4A2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US claimed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US claimed
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US disclosed
CN-101878211-A Aminothiazole derivs HOFFMANN LA ROCHE 2010-11-03 CN disclosed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US disclosed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES FBP1, SLC5A1, DPP4 CA9 2185/4885CA12 4148/4885CA1 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.